Celldex Therapeutics

US · CLDX #2630 by market cap Listed 1970

30.43 -0.58 -1.85%

Live - 5344 symbols - heartbeat 21s ago · 2026-10-08 06:17

Pre-market 30.24 -0.63%

After-hours 30.51 +0.26%

Market cap: 2.39B
P/E (TTM): -7.00
P/B: 3.34
EPS: -3.90
Div yield: 0.00%
52W pos: 36%

Reader sentiment Are you bullish or bearish on CLDX?

Anonymous reader poll. Unscientific, not investment advice.

About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Founded: 1983
CEO: Mr. Anthony S. Marucci
Employees: 198
Headquarters: Hampton, New Jersey, United States of America
Fiscal year end: 12-31
Website: celldex.com

Company profile

Exchange: US
Symbol: CLDX
Market-cap rank: #2630
Listing date: 1970-01-01
Market cap: 2.39B
Float cap: 2.22B
Shares out: 78.53M
Float shares: 73.02M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 06:17:29 · For reference only, not investment advice and not tailored to your situation.